Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms.
The bothersome vasomotor and vaginal symptoms and bone loss that accompany the menopausal transition are associated with significant direct costs due to physician visits and medication, as well as indirect costs from reduced health-related quality of life (HRQoL) and work productivity. With life expectancies increasing, the number of postmenopausal women is also increasing, and more women are remaining in the workforce. These factors have led to an increased burden of menopausal symptoms on healthcare systems. Hormone therapy (HT) has been shown to effectively reduce menopausal symptoms and significantly increase quality-adjusted life years in postmenopausal women, particularly in women experiencing severe symptoms. However, many women discontinue use of HT before their symptoms have dissipated due to safety and tolerability concerns. The tissue selective estrogen complex (TSEC) that pairs bazedoxifene (BZA) with conjugated estrogens (CE) has been developed to provide relief of menopausal symptoms and prevent bone loss without stimulating the breast or endometrium, and to have improved tolerability compared with HT. In this context, BZA 20mg/CE 0.45 and 0.625 mg were shown to prevent bone loss and effectively treat menopausal symptoms in postmenopausal women with an intact uterus, while also demonstrating a favorable safety/tolerability profile. BZA 20mg/CE 0.45 and 0.625 mg were further associated with clinically significant improvements in HRQoL, sleep, and treatment satisfaction. Taken together, the reduction in menopausal symptoms, improvement in HRQoL, and favorable safety/tolerability profile associated with BZA/CE suggest that it is a cost-effective alternative to HT for managing the burden of menopausal symptoms.
Pfizer Inc., Collegeville, PA, United States. Electronic address: Sebastian.Mirkin@pfizer.com.
Sebastian
S
Mirkin
Pfizer Inc., Collegeville, PA, United States.
Kelly A
KA
Ryan
Pfizer Inc., New York, NY, United States.
Arthi B
AB
Chandran
Pfizer Inc., Collegeville, PA, United States.
Barry S
BS
Komm
D004967:Estrogens / Q000172:deficiency / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D019584:Hot Flashes / Q000517:prevention & control; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008593:Menopause; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D007211:Indoles; D020845:Selective Estrogen Receptor Modulators; C447119:bazedoxifene
Bazedoxifene; Hormone therapy; Menopause; Vasomotor symptoms